Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

Similar articles for PubMed (Select 20078897)

1.

Household costs of illness during different phases of tuberculosis treatment in Central Asia: a patient survey in Tajikistan.

Ayé R, Wyss K, Abdualimova H, Saidaliev S.

BMC Public Health. 2010 Jan 18;10:18. doi: 10.1186/1471-2458-10-18.

2.

The high cost of free tuberculosis services: patient and household costs associated with tuberculosis care in Ebonyi State, Nigeria.

Ukwaja KN, Alobu I, Lgwenyi C, Hopewell PC.

PLoS One. 2013 Aug 27;8(8):e73134. doi: 10.1371/journal.pone.0073134. eCollection 2013.

3.

Tuberculosis and poverty: the contribution of patient costs in sub-Saharan Africa--a systematic review.

Barter DM, Agboola SO, Murray MB, Bärnighausen T.

BMC Public Health. 2012 Nov 14;12:980. doi: 10.1186/1471-2458-12-980. Review.

4.

The economic burden of tuberculosis care for patients and households in Africa: a systematic review.

Ukwaja KN, Modebe O, Igwenyi C, Alobu I.

Int J Tuberc Lung Dis. 2012 Jun;16(6):733-9. doi: 10.5588/ijtld.11.0193. Epub 2012 Mar 8. Review.

PMID:
22410546
5.

Patients are paying too much for tuberculosis: a direct cost-burden evaluation in Burkina Faso.

Laokri S, Drabo MK, Weil O, Kafando B, Dembélé SM, Dujardin B.

PLoS One. 2013;8(2):e56752. doi: 10.1371/journal.pone.0056752. Epub 2013 Feb 25.

6.

Economic evaluation of public-private mix for tuberculosis care and control, India. Part I. Socio-economic profile and costs among tuberculosis patients.

Pantoja A, Floyd K, Unnikrishnan KP, Jitendra R, Padma MR, Lal SS, Uplekar M, Chauhan LS, Kumar P, Sahu S, Wares F, Lönnroth K.

Int J Tuberc Lung Dis. 2009 Jun;13(6):698-704.

PMID:
19460244
7.

Illness costs to households are a key barrier to access diagnostic and treatment services for tuberculosis in Tajikistan.

Ayé R, Wyss K, Abdualimova H, Saidaliev S.

BMC Res Notes. 2010 Dec 20;3:340. doi: 10.1186/1756-0500-3-340.

8.

Cost-effectiveness of different treatment strategies for tuberculosis in Egypt and Syria.

Vassall A, Bagdadi S, Bashour H, Zaher H, Maaren PV.

Int J Tuberc Lung Dis. 2002 Dec;6(12):1083-90.

PMID:
12546116
9.

Costs and cost-effectiveness of different DOT strategies for the treatment of tuberculosis in Pakistan. Directly Observed Treatment.

Khan MA, Walley JD, Witter SN, Imran A, Safdar N.

Health Policy Plan. 2002 Jun;17(2):178-86.

11.

Financial burden for tuberculosis patients in low- and middle-income countries: a systematic review.

Tanimura T, Jaramillo E, Weil D, Raviglione M, Lönnroth K.

Eur Respir J. 2014 Jun;43(6):1763-75. doi: 10.1183/09031936.00193413. Epub 2014 Feb 13. Review.

12.

[Tuberculosis in Asia].

[No authors listed]

Kekkaku. 2002 Oct;77(10):693-7. Japanese.

PMID:
12440145
13.

Economic evaluation of public-private mix for tuberculosis care and control, India. Part II. Cost and cost-effectiveness.

Pantoja A, Lönnroth K, Lal SS, Chauhan LS, Uplekar M, Padma MR, Unnikrishnan KP, Rajesh J, Kumar P, Sahu S, Wares F, Floyd K.

Int J Tuberc Lung Dis. 2009 Jun;13(6):705-12.

PMID:
19460245
14.

Free tuberculosis diagnosis and treatment are not enough: patient cost evidence from three continents.

Mauch V, Bonsu F, Gyapong M, Awini E, Suarez P, Marcelino B, Melgen RE, Lönnroth K, Nhung NV, Hoa NB, Klinkenberg E.

Int J Tuberc Lung Dis. 2013 Mar;17(3):381-7. doi: 10.5588/ijtld.12.0368.

PMID:
23407227
15.

Patient's site of first access to health system influences length of delay for tuberculosis treatment in Tajikistan.

Ayé R, Wyss K, Abdualimova H, Saidaliev S.

BMC Health Serv Res. 2010 Jan 10;10:10. doi: 10.1186/1472-6963-10-10.

16.

Social franchising of TB care through private GPs in Myanmar: an assessment of treatment results, access, equity and financial protection.

Lönnroth K, Aung T, Maung W, Kluge H, Uplekar M.

Health Policy Plan. 2007 May;22(3):156-66. Epub 2007 Apr 12.

17.

Cost of disorders of the brain in Europe 2010.

Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, Dodel R, Ekman M, Faravelli C, Fratiglioni L, Gannon B, Jones DH, Jennum P, Jordanova A, Jönsson L, Karampampa K, Knapp M, Kobelt G, Kurth T, Lieb R, Linde M, Ljungcrantz C, Maercker A, Melin B, Moscarelli M, Musayev A, Norwood F, Preisig M, Pugliatti M, Rehm J, Salvador-Carulla L, Schlehofer B, Simon R, Steinhausen HC, Stovner LJ, Vallat JM, Van den Bergh P, van Os J, Vos P, Xu W, Wittchen HU, Jönsson B, Olesen J; CDBE2010Study Group.

Eur Neuropsychopharmacol. 2011 Oct;21(10):718-79. doi: 10.1016/j.euroneuro.2011.08.008. Epub 2011 Sep 15. Erratum in: Eur Neuropsychopharmacol. 2012 Mar;22(3):237-8. den Bergh, Peter Van [corrected to Van den Bergh, Peter].

PMID:
21924589
18.

Patients' costs and cost-effectiveness of tuberculosis treatment in DOTS and non-DOTS facilities in Rio de Janeiro, Brazil.

Steffen R, Menzies D, Oxlade O, Pinto M, de Castro AZ, Monteiro P, Trajman A.

PLoS One. 2010 Nov 17;5(11):e14014. doi: 10.1371/journal.pone.0014014.

19.

Cost-effectiveness of treating multidrug-resistant tuberculosis.

Resch SC, Salomon JA, Murray M, Weinstein MC.

PLoS Med. 2006 Jul;3(7):e241.

20.

Assessing the economic burden of illness for tuberculosis patients in Benin: determinants and consequences of catastrophic health expenditures and inequities.

Laokri S, Dramaix-Wilmet M, Kassa F, Anagonou S, Dujardin B.

Trop Med Int Health. 2014 Oct;19(10):1249-58. doi: 10.1111/tmi.12365. Epub 2014 Jul 18.

PMID:
25040399
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk